I give Tofacitinib a 75% chance to be endorsed by a solid plurality of the advisory panel (i.e. something better than a 7-5 or 8-7 vote in favor). Does anyone here agree/disagree?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”